Loading...
XNYS
SOLV
Market cap13bUSD
Jul 09, Last price  
75.96USD
1D
1.04%
1Q
15.46%
IPO
9.93%
Name

Solventum Corp

Chart & Performance

D1W1MN
XNYS:SOLV chart
P/E
8.43
P/S
1.58
EPS
9.01
Div Yield, %
Shrs. gr., 5y
0.33%
Rev. gr., 5y
2.72%
Revenues
8.33b
+0.86%
7,281,000,0008,171,000,0008,130,000,0008,197,000,0008,254,000,0008,325,000,000
Net income
1.56b
+224.84%
1,138,000,0001,460,000,0001,343,000,0001,346,000,000479,000,0001,556,000,000
CFO
369m
-68.86%
2,026,000,0002,202,000,0001,679,000,0001,915,000,0001,185,000,000369,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
IPO date
Mar 26, 2024
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT